Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling

作者: Arturo Molina , Arie Belldegrun

DOI: 10.1016/J.JURO.2010.10.042

关键词:

摘要: Purpose: Androgen receptor signaling remains essential for many prostate cancers that have progressed despite androgen deprivation therapy. After medical or surgical castration persistent though not insignificant low levels of androgens are produced from nongonadal sources, such as the adrenal glands. Some resistant acquire ability to convert steroids androgens, maintaining sufficient activate receptor. Inhibition production and mediated relevant therapeutic strategies cancer.Materials Methods: The scientific foundation clinical experience with secondary hormonal therapy well development new investigational agents cancer, specifically selective cytochrome p450 17 inhibitors second generation antiandrogens, discussed.Results: Selective inhibition has emerged an importa...

参考文章(51)
Philip W. Kantoff, Susan Halabi, Mark Conaway, Joel Picus, Jeffrey Kirshner, Vera Hars, Donald Trump, Eric P. Winer, Nicholas J. Vogelzang, Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Journal of Clinical Oncology. ,vol. 17, pp. 2506- 2513 ,(1999) , 10.1200/JCO.1999.17.8.2506
S. D. Fosså, P. H.Th. Slee, M. Brausi, S. Horenblas, R. R. Hall, J. W. Hetherington, N. Aaronson, L. de Prijck, L. Collette, Flutamide Versus Prednisone in Patients With Prostate Cancer Symptomatically Progressing After Androgen-Ablative Therapy: A Phase III Study of the European Organization for Research and Treatment of Cancer Genitourinary Group Journal of Clinical Oncology. ,vol. 19, pp. 62- 71 ,(2001) , 10.1200/JCO.2001.19.1.62
H I Scher, C Liebertz, W K Kelly, M Mazumdar, C Brett, L Schwartz, G Kolvenbag, L Shapiro, M Schwartz, Bicalutamide for advanced prostate cancer: the natural versus treated history of disease Journal of Clinical Oncology. ,vol. 15, pp. 2928- 2938 ,(1997) , 10.1200/JCO.1997.15.8.2928
David C Smith, Bruce G Redman, Lawrence E Flaherty, Lang LI, Myla Strawderman, Kenneth J Pienta, A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer Urology. ,vol. 52, pp. 257- 260 ,(1998) , 10.1016/S0090-4295(98)00173-3
Charlie D Chen, Derek S Welsbie, Chris Tran, Sung Hee Baek, Randy Chen, Robert Vessella, Michael G Rosenfeld, Charles L Sawyers, Molecular determinants of resistance to antiandrogen therapy Nature Medicine. ,vol. 10, pp. 33- 39 ,(2004) , 10.1038/NM972
Jeff Holzbeierlein, Priti Lal, Eva LaTulippe, Alex Smith, Jaya Satagopan, Liying Zhang, Charles Ryan, Steve Smith, Howard Scher, Peter Scardino, Victor Reuter, William L. Gerald, Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance American Journal of Pathology. ,vol. 164, pp. 217- 227 ,(2004) , 10.1016/S0002-9440(10)63112-4
James A. Storlie, Jan C. Buckner, Gregory A. Wiseman, Patrick A. Burch, Lynn C. Hartmann, Ronald L. Richardson, Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma Cancer. ,vol. 76, pp. 96- 100 ,(1995) , 10.1002/1097-0142(19950701)76:1<96::AID-CNCR2820760114>3.0.CO;2-E
Tadas Vasaitis, Aashvini Belosay, Adam Schayowitz, Aakanksha Khandelwal, Pankaj Chopra, Lalji K. Gediya, Zhiyong Guo, Hong-Bin Fang, Vincent C.O. Njar, Angela M.H. Brodie, Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer Molecular Cancer Therapeutics. ,vol. 7, pp. 2348- 2357 ,(2009) , 10.1158/1535-7163.MCT-08-0230